Similar articles

• Exenatide suppresses postprandial elevations in lipids and lipoproteins in individuals with impaired glucose tolerance and recent onset type 2 diabetes mellitus.

  Schwartz EA, Koska J, Mullin MP, Syoufi I, Schwenke DC, Reaven PD. Schwartz EA, et al. Atherosclerosis. 2010 Sep;212(1):217-22. doi: 10.1016/j.atherosclerosis.2010.05.028. Epub 2010 May 25. Atherosclerosis. 2010. PMID: 20557887 Clinical Trial.
• One-year treatment with exenatide vs. insulin glargine: effects on postprandial glycemia, lipid profiles, and oxidative stress.

  Bunck MC, Cornér A, Eliasson B, Heine RJ, Shaginian RM, Wu Y, Yan P, Smith U, Yki-Järvinen H, Diamant M, Taskinen MR. Bunck MC, et al. Atherosclerosis. 2010 Sep;212(1):223-9. doi: 10.1016/j.atherosclerosis.2010.04.024. Epub 2010 Apr 29. Atherosclerosis. 2010. PMID: 20494360 Clinical Trial.
• Exenatide, a glucagon-like peptide-1 receptor agonist, acutely inhibits intestinal lipoprotein production in healthy humans.

  Xiao C, Bandsma RH, Dash S, Szeto L, Lewis GF. Xiao C, et al. Arterioscler Thromb Vasc Biol. 2012 Jun;32(6):1513-9. doi: 10.1161/ATVBAHA.112.246207. Epub 2012 Apr 5. Arterioscler Thromb Vasc Biol. 2012. PMID: 22492091 Clinical Trial.
• The incretin system: glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in type 2 diabetes.

  Drucker DJ, Nauck MA. Drucker DJ, et al. Lancet. 2006 Nov 11;368(9548):1696-705. doi: 10.1016/S0140-6736(06)69705-5. Lancet. 2006. PMID: 17098089 Review.
• Clinical efficacy and safety of once-weekly glucagon-like peptide-1 agonists in development for treatment of type 2 diabetes mellitus in adults.

  Tzefos M, Harris K, Brackett A. Tzefos M, et al. Ann Pharmacother. 2012 Jan;46(1):68-78. doi: 10.1345/aph.1Q379. Ann Pharmacother. 2012. PMID: 22232377 Review.